NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Drug Manufacturers - Specialty & Generic · USD

Glass House Brands Inc. (GLAS) Stock Analysis

Glass House Brands Inc. (GLAS) is a Drug Manufacturers - Specialty & Generic stock listed on NYSE and quoted in US Dollar.

GLAS

$8.88

+$0.28 (+3.26%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GLAS with… →

GLAS Key Statistics

As of Sep 4, 2026
Trading
Open
$8.60
Previous Close
$8.60
Day's Range
8.55–9.03
52-Week Range
5.15–13.93
Volume
482.14K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.63
Valuation
Market Cap
$836.87M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
39.47
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.73
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.80
Financials (FY)
Revenue (FY)
$181.98M−9.41%
Net Income (FY)
−$29.66M−5814.64%
Profit marginThe share of revenue left as profit after all costs and taxes.
−29.50%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
88.00M
1-Year Return
+22.31%
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
413.50K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

GLAS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+0.34%
2025+52.59%
2024+22.62%
2023+147.64%
2022−50.17%
2021−62.01%
2020+4.24%
2019 (partial year)−1.23%

As of September 4, 2026.

GLAS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$181.98M−$29.66M−16.3%
2024$200.90M$519.00K0.3%
2023$160.84M−$98.27M−61.1%
2022$84.87M−$32.90M−38.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$181.98M$76.96M−$14.63M−$29.66M−16.3%
2024$200.90M$97.39M$12.04M$519.00K0.3%
2023$160.84M$80.97M$3.29M−$98.27M−61.1%
2022$84.87M$20.71M−$50.54M−$32.90M−38.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

GLAS Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricGLASDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio4.732.30106% above
Profit margin−29.50%−3.14%26.4 pts below

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Glass House Brands Inc. (GLAS) is capitalised at $836.87M on the latest close. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. Headcount on file is 357.

The 52-week range on file runs from $5.15 to $13.93. The most recent close on file for GLAS is $8.88, dated September 4, 2026. That is +$0.28 (+3.26%) against the previous close. The latest close sits 72.43% above that 52-week low.

Financial Health

In fiscal 2025, Glass House Brands Inc. reported revenue of $181.98M. Against the prior fiscal year total of $200.90M, that is a change of −9.41%. The same year closed with a net loss of $29.66M. Profit margin runs at −29.5%. That is 26.4 percentage points below the Drug Manufacturers - Specialty & Generic median of −3.14%. Earnings per share on a trailing basis come to −0.8.

Across the 4 fiscal years on file, revenue moves from $84.87M in 2022 to $181.98M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The forward P/E on file is 39.47. The price-to-sales ratio is 4.73. On price-to-sales that is 105.93% above the Drug Manufacturers - Specialty & Generic median of 2.3. The medians here are taken across 103 Drug Manufacturers - Specialty & Generic companies that report the metric.

Over the trailing twelve months the price has returned +22.31%. Across 5 years the annualized return works out at +10.18%. Beta against the wider market is reported at 0.63. Annualized volatility over the trailing 7 years is 69.65%.

Growth & Income

The record shows no dividend for GLAS.

The strongest complete calendar year on file is 2023 at +147.64%; the weakest is 2021 at −62.01%. Of the 6 complete calendar years on file, 4 finished higher. So far in 2026 the price is +0.34%.

Peer Comparison

Glass House Brands Inc. (GLAS) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Glass House Brands Inc. GLAS $836.87M —
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 19.6

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.1x. Glass House Brands Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Glass House Brands Inc.

Glass House Brands Inc., together with its subsidiaries, operates as an integrated cannabis company in the United States. It operates through three segments: Retail; Wholesale Biomass; and Cannabis-Related Consumer Packaged Goods. The Retail segment owns, and operates retail cannabis stores, and dispensary operation management services. The Wholesale Biomass segment includes propagation, nursery, flowering canopy, dries, processes, and distributes cannabis biomass. The Cannabis-Related Consumer Packaged Goods segment manufactures, extracts, infuse, conversion, packaging, and distributes cannabis products. The company cultivates, manufactures, and distributes cannabis bulk flowers and trims to wholesalers; and consumer packaged goods to third-party retail stores in California. It also offers raw cannabis, cannabis oil, and cannabis consumer goods; edibles; flower jars and bags; single, multi-pack, and infused pre-rolls; tinctures; biomass for distributors; and online payment processing, in-store pickup and home delivery services for adult-use and medicinal-use customers. The company serves its cannabis products under the Glass House Farms, PLUS, Allswell, REEFORM, and Mama Sue brand names. Glass House Brands Inc. was founded in 2015 and is headquartered in Long Beach, California.

Visit website →